not sure how you post this with such conviction when you have no idea what you’re talking about. The audit is ongoing through the year, 1.5months? No. Cettire is absolutely not one of GTs main clients, it’s still a relatively small and straightforward company from an accounting perspective.
you have to remember it’s still basically Dean and a handful of employees that have achieved an incredible amount in a short period of time. They paid around 400k in audit fees which is a relatively small job.
Yes they have an argument with management which is in the end inconsequential. The delivered margin number will become revenue and profit remains the same.
if however, I’m the issue with GT is more than revenue recognition than we have an issue, but the company is saying that this is the only substantive issue and the only outcomes here are they state revenue in one of two ways.
there is no doubt here about not issuing a clean opinion, this is baseless speculation.
- Forums
- ASX - By Stock
- CTT
- Ann: FY24 Results Presentation
CTT
cettire limited
Add to My Watchlist
5.80%
!
36.5¢

Ann: FY24 Results Presentation, page-69
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
36.5¢ |
Change
0.020(5.80%) |
Mkt cap ! $139.1M |
Open | High | Low | Value | Volume |
34.5¢ | 37.5¢ | 34.5¢ | $3.364M | 9.250M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 313504 | 35.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.5¢ | 45549 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 145155 | 0.350 |
2 | 62500 | 0.345 |
4 | 35764 | 0.340 |
2 | 26432 | 0.335 |
1 | 2000 | 0.330 |
Price($) | Vol. | No. |
---|---|---|
0.365 | 45549 | 2 |
0.370 | 13951 | 2 |
0.375 | 267987 | 4 |
0.380 | 79396 | 7 |
0.385 | 18000 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
CTT (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online